|
|
West Pharmaceutical Services Inc (NYSE: WST) |
|
Price: $223.4700
$-1.44 
-0.640%
|
| Day's High:
| $223.47
| Week Perf:
| -2.28 %
|
| Day's Low: |
$ 223.03 |
30 Day Perf: |
1.7 % |
| Volume (M): |
7 |
52 Wk High: |
$ 397.72 |
| Volume (M$): |
$ 1,472 |
52 Wk Avg: |
$313.62 |
| Open: |
$226.10 |
52 Wk Low: |
$197.01 |
|
|
| Market Capitalization (Millions $) |
16,458 |
| Shares
Outstanding (Millions) |
74 |
| Employees |
10,600 |
| Revenues (TTM) (Millions $) |
2,893 |
| Net Income (TTM) (Millions $) |
493 |
| Cash Flow (TTM) (Millions $) |
-369 |
| Capital Exp. (TTM) (Millions $) |
377 |
West Pharmaceutical Services Inc
West Pharmaceutical Services, Inc. is a prominent player in the global healthcare and pharmaceutical sectors, specializing in the development and manufacture of innovative packaging components and delivery systems for injectable drugs and medical products. Headquartered in Exton, Pennsylvania, the company has a rich history dating back to its incorporation in 1923, reflecting a longstanding commitment to advancing injectable drug delivery solutions.
Key Products and Services
Wests comprehensive product portfolio includes:
1. Vial Containment Solutions: These are designed to safeguard pharmaceuticals from contamination and ensure safe storage and dispensing.
2. Prefillable Systems: West offers prefilled syringes and associated components that enhance convenience and accuracy in drug delivery, catering specifically to biologics and other sensitive pharmaceuticals.
3. Self-Injection Platforms: This range allows patients to administer their medications independently, providing greater flexibility and control over their healthcare.
4. Cartridge Systems: These systems facilitate the safe and efficient delivery of medications, often used in conjunction with pen injectors and other delivery devices.
5. Reconstitution and Transfer Systems: West provides solutions for effectively mixing and transferring medications, particularly important for lyophilized drugs that require a reconstitution step before administration.
6. Intradermal Delivery Solutions: Innovative systems that allow for targeted delivery of medications to the skin or dermal layers, addressing specific therapeutic needs.
Specialty Components: These products are designed for unique applications within the pharmaceutical industry, tailored to meet specific client requirements.
8. Contract Manufacturing and Analytical Services: West offers these services to support clients in producing high-quality drug delivery systems, ensuring regulatory compliance and meeting stringent industry standards.
Customer Base
West Pharmaceutical Services serves a diverse and distinguished clientele, including leading companies in the biotechnology, generic drugs, pharmaceutical, diagnostics, and medical device sectors. This extensive customer base highlights Wests pivotal role in the pharmaceutical supply chain, contributing to advancements in drug delivery and patient care.
Global Presence
West operates numerous facilities around the globe, reinforcing its ability to meet worldwide demand and support multinational pharmaceutical companies. This global footprint also enables the company to leverage various regional markets' opportunities while adhering to local regulatory environments.
Commitment to Innovation
The company invests significantly in research and development to drive innovation in its product offerings, focusing on enhancing the safety, efficiency, and ease of use in drug delivery systems. This commitment positions West at the forefront of the industry, helping to address evolving healthcare needs and improving patient outcomes.
Recent Developments
In recent years, West has continued to expand its capabilities and product offerings to adapt to changing market demands, such as the increased focus on biologics and biosimilars. This has included partnerships, collaborations, and strategic investments aimed at elevating their technology and product innovation.
Conclusion
West Pharmaceutical Services, Inc. stands out as a crucial entity in the manufacturing and development of packaging components and delivery systems essential for modern healthcare. With decades of expertise, a commitment to quality, and a broad array of innovative solutions, West remains dedicated to advancing the pharmaceutical and biotechnology industries.
Company Address: 530 Herman O. West Drive Exton 19341 PA
Company Phone Number: 594-2900 Stock Exchange / Ticker: NYSE WST
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| West Pharmaceutical Services Inc
West Pharmaceutical Services Inc: Analyzing Disappointing Q3 2024 Financial Results Amidst Positive Market PerformanceWest Pharmaceutical Services Inc., a key player in the Medical Equipment & Supplies sector, recently released its third-quarter earnings for 2024, revealing a mixed bag of results that have sparked both concern and cautious optimism. This article delves into the financial metrics reported, highlights the challenges faced by the company, and provides context regarding its recent stock performance.Financial Highlights of Q3 20241. Earnings Per Share (EPS): - The company's EPS deteriorated by 13.55%, dropping from $2.14 to $1.85 year-on-year. This decline is a significant concern, as EPS is a critical indicator of a company's profitability on a per-share basis.
|
| Stocks on the Move
Published Wed, Aug 21 2024 10:41 AM UTC
West Pharmaceutical Services: A Closer Look at the Recent Sell-Off and Second Quarter Performance ResultsIn recent news, West Pharmaceutical Services Inc. (NYSE: WST) has faced significant challenges in the stock market, underperforming its competitors and experiencing a decrease in profits and revenues in the second quarter of 2024. With a 52-week high of $415.73, the stock...
|
| West Pharmaceutical Services Inc
Financial Report: West Pharmaceutical Services Inc Faces Declining Income and Revenue
West Pharmaceutical Services Inc, a global leader in innovative solutions for injectable drug administration, has reported a drop in income and revenue for the April to June 30, 2024 financial period. The company's income per share plummeted by -26.7% to $1.51 compared to $2.06 per share a year ago. Additionally, income per share decreased by -2.58% from $1.55 per share in the previous reporting period.
The decline in income is mirrored by a decrease in revenue, which sank by -6.872% to $702.00 million from $753.80 million in the same financial reporting period last year. However, there was a sequential revenue advancement of 0.978%, with revenue increasing from $695.20 million.
|
| West Pharmaceutical Services Inc
Investors in West Pharmaceutical Services Inc (NYSE: WST) may be feeling concerned following the disappointing first-quarter results announced by the company. The earnings per share deteriorated by -16.22% to $1.55 from $1.85, and revenue sunk by -2.986% to $695.20 million in the first quarter of the 2024 earnings season, year on year.
Comparing these results to the rest of the Medical Equipment & Supplies sector, where other companies posted revenue gains in the same period, it is clear that West Pharmaceutical Services Inc is facing some challenges. Profits fell from $1.84 per share and revenue decreased by -4.962% from $731.50 million in the preceding financial reporting period. Net income also saw a decline by -17.64% to $115.300 million in the first quarter of 2024.
|
| West Pharmaceutical Services Inc
In the final fiscal quarter of 2023, West Pharmaceutical Services Inc exhibited strong growth in its earnings per share, outpacing the increase in revenue. The company reported a 34.8% surge in profit per share, reaching $1.84 per share, while revenue saw a moderate increase of 3.217% to $731.50 million compared to the same quarter in the previous year. However, when compared to its competitors in the Medical Equipment & Supplies sector, West Pharmaceutical Services Inc fell short in terms of top-line growth, as the sector as a whole saw a 5.58% increase in revenue from the previous year.
In the previous quarter, the company reported revenue of $747.30 million and earnings of $2.14 per share. The bottom line for the fourth quarter of 2023 showed significant improvement, with net earnings of $137.000 million, a 33.01% increase from the same period a year ago. Profit margins also saw improvement, with net margin rising to 18.73% and operating margin increasing to 22% in the fourth quarter of 2023. Additionally, the company experienced a build-up in inventories, with levels reaching $434.7 million, higher than both the previous quarter and the same period a year ago.
|
| Per Share |
Current |
| Earnings (TTM) |
6.7 $ |
| Revenues (TTM) |
39.28 $
|
| Cash Flow (TTM) |
- |
| Cash |
6.58 $
|
| Book Value |
36.42 $
|
| Dividend (TTM) |
0.8 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
6.7 $
|
| Revenues (TTM) |
39.28 $ |
| Cash Flow (TTM) |
- |
| Cash |
6.58 $
|
| Book Value |
36.42 $ |
| Dividend (TTM) |
0.8 $ |
|
|
| |
| Proprietary Products |
|
 80.54 % |
of total Revenue |
| Contract-Manufactured Products |
|
19.49 % |
of total Revenue |
|
|
1.24% 